NICE rejects Novartis’ Mayzent for secondary progressive MS
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
Read More
Tag: siponimod
Novartis highlights benefits of Mayzent in MS
The data underscore the advantages of early treatment initiation, the firm notes
Read More
Novartis files MS drug siponimod in EU and US
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
Read More
US, EU filings imminent for Novartis’ MS therapy siponimod
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.
Read More
Novartis’ siponimod hits targets in MS trial
Novartis has unveiled further findings from a late-stage trial of its experimental multiple sclerosis drug BAF312 (siponimod), showing that the drug cut the risk of disability progression in adults with secondary progressive forms of the disease.
Read More
Novartis’ MS drug hits primary PhIII target
Novartis’ experimental multiple sclerosis drug siponimod has hit its key target in a late-stage trial, raising hopes for a new treatment option for patients.
Read More
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
